In a previous study of 55 patients with HER2-positive breast cancer who received trastuzumab plus pertuzumab neoadjuvant therapy, pCR positively related to high expression levels of AR (OR 33.145, 95% CI 2.803 to 391.900, P = 0.005) [29]. Here, AR is linked to breast carcinoma.